Trastuzumab duocarmazine is a HER2-targeting antibody-drug conjugate comprised of trastuzumab bound to a linker drug containing duocarmycin. Trastuzumab duocarmazine has been used in the research of HER2-positive locally advanced or metastatic breast cancer therary.
Structure of 1642152-40-6
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00023 | Trastuzumab emtansine | 1018448-65-1 | |
BADC-01602 | Trastuzumab deruxtecan | 1826843-81-5 | |
BADC-01347 | Trastuzumab-MC-MMAE |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.